- Reuters•11 hours ago
Pharmaceutical company Mylan NV has won a round in its fight with Teva Pharmaceutical Industries Ltd at the U.S. Patent and Trademark Office, which said on Wednesday that two patents for the multiple sclerosis drug Copaxone sold by Teva were, after a review process, considered unpatentable. The USPTO did not immediately have a decision on a third patent for Copaxone that it is also considering reviewing. Teva sells Copaxone based on patents licensed from Yeda Research & Development Co Ltd.
- CNBC•11 hours ago
Shares of Teva Pharmaceuticals fell as much as 6 percent on Wednesday after the U.S. Patent Office invalidated two of the company's patents.
- Business Wire•12 hours ago
Teva Pharmaceutical Industries Ltd. today confirmed the Patent Trial and Appeal Board decisions from an Inter Partes Review to invalidate all claims of the ‘250 and ‘413 patents for 40 mg COPAXONE® .
Teva Pharmaceutical Industries Limited (TEVA)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||51.77 x 600|
|Ask||51.99 x 1000|
|Day's Range||49.87 - 53.96|
|52wk Range||48.01 - 66.55|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||34.49|
|Avg Vol (3m)||5,648,640|
|Dividend & Yield||1.36 (2.56%)|